Kangwei Century Biotechnology Co., Ltd. has a registered capital of 69.87 million yuan. The company is a national high-tech enterprise , based in the field of life sciences and has independent intellectual property rights. It is mainly engaged in the research, development and production of biological reagent with high value-added and high-tech content, and provides innovative biological products and services for life science research, gene detection and in vitro diagnosis users. The company has been successively rated as a national high-tech enterprise, a science and technology-based small and medium-sized enterprise in Jiangsu Province, a gazelle enterprise in Jiangsu Province, and a private technology enterprise in Jiangsu Province. The company has established a professional, intensive and capable of forming a technological innovation system and an open cooperative innovation platform that is professional and intensive, and has built a complete R&D innovation system for the company.
product line mainly includes molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents, etc., breaking the dependence of China's biological research and industry on imported reagents.
has a group of experts from all fields of biotechnology, and has made achievements in many fields of innovation and research and development, forming good complementary advantages. The company has 6 technical platforms and a total of 23 core molecular testing technologies. The core products include various PCR enzymes, buffer , nucleic acid protection agents, nucleic acid extraction kits, second-generation sequencing library building kits, molecular diagnostic detection reagents, etc.
This time, the company plans to issue 23.290278 million shares, with a total share capital of 93.16111 million shares after issuance, with an issue price of 48.98 yuan per share.
1. Main business
The company is based on independent research and development of the underlying core technologies of molecular testing, and has accumulated more than ten years of R&D in the fields of enzyme raw materials, nucleic acid preservation, and sample pretreatment. It is one of the few biotechnology companies in China that have achieved a complete business layout in the core links of molecular testing. The company's core products include molecular detection enzyme raw materials, nucleic acid preservation reagents, nucleic acid extraction and purification reagents, and molecular diagnostic kits. The reagents developed by the company play an important role in the efficiency and accuracy of results of molecular detection; at the same time, based on the technical advantages of each core link of molecular detection, the company has expanded its business to the screening and diagnosis of digestive tract diseases and respiratory infectious diseases, and has developed a number of innovative products and services, realizing the integrated layout of "core enzyme raw materials + kits + detection services" in molecular detection.
2. Main financial data and financial indicators
(1) Financial data and financial indicators in the past three years:
(2) Financial information and audit base date from January to June 2022:
From January to June 2022, the company achieved operating income of 265.5669 million yuan, an increase of 110.23% year-on-year; the company achieved net profit attributable to parent company shareholders and net profit attributable to parent company shareholders after deducting non-recurring gains and losses , respectively, were 100.9161 million yuan, 100.0628 million yuan and 9577.77 10,000 yuan, an increase of 144.82%, 142.75% and 171.67% over the same period last year. From January to June 2022, the company's operating income and net profit achieved rapid growth year-on-year. The main reason was that the company's market expansion work was steadily progressing, various businesses continued to advance, as well as the normal prevention and control of the domestic COVID-19 epidemic and the spread of global COVID-19 variant strains continued to ferment, which made the demand for molecular testing-related products still relatively strong, driving a significant improvement in the company's performance.
(3) Performance forecast for January-September 2022:
expects performance in January-September 2022 to achieve growth compared with the same period last year. The company expects operating income from January to September 2022 to be RMB 390 million to RMB 400 million, an increase of 68.19% to 72.50% over the same period last year; the net profit attributable to the parent company shareholders is RMB 145 million to RMB 150 million, an increase of 64.47% to 70.14% over the same period last year; the net profit attributable to the parent company shareholders after deducting non-recurring gains and losses is RMB 135 million to RMB 140 million, an increase of 69.10% to 75.36% over the same period last year. Affected by the continued growth in demand for molecular testing products in the market, the company's performance has increased significantly compared with the same period last year. The company's main operating conditions are normal and its operating performance continues to grow. No major matters that have an impact on the company's continued operating capabilities or may affect investors' judgments.
3. Investment projects raised funds
4. Stock issuance price and earnings ratio
This issue price is 48.98 yuan/share corresponding to the issuer. The diluted price-earnings ratio of 40.80 times in 2021 after audited deduction of non-recurring gains and losses is 40.80 times, which is higher than the industry's average static price-earnings ratio released by CSI Index Co., Ltd. . The average static price-earnings ratio of 22.71 times in the past month, and it is also higher than the average static price-earnings ratio of comparable companies in the same industry 33.84 times. Therefore, after the stock is listed, there is a risk of future stock price declines to investors.
5. Subscription risk
shares are issued on Shanghai Science and Technology Innovation Board . The issuance price-to-earnings ratio is much higher than the price-to-earnings ratio of comparable listed companies in the same industry. There is a high risk of breaking the issue, so please subscribe carefully.
6. Special statement
1. In addition to the above subscription risk judgment content, other information mainly comes from the company's prospectus, the company's official website and publicly released information.
2. New stocks are risky, so be cautious when applying.
